S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Musk says Twitter deal could move ahead with 'bot' info
pixel
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Musk says Twitter deal could move ahead with 'bot' info
pixel
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Musk says Twitter deal could move ahead with 'bot' info
pixel
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Musk says Twitter deal could move ahead with 'bot' info
pixel
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
pixel
OTCMKTS:DMCAF

DiaMedica Therapeutics - DMCAF Stock Forecast, Price & News

$1.69
-0.01 (-0.59%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.66
$1.72
50-Day Range
$1.27
$2.49
52-Week Range
$0.38
$0.38
Volume
57,731 shs
Average Volume
131,151 shs
Market Capitalization
$265.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DiaMedica Therapeutics logo

About DiaMedica Therapeutics (OTCMKTS:DMCAF) Stock

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive DMCAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMCAF Stock News Headlines

See More Headlines

Receive DMCAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:DMCAF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$265.57 million
Optionable
Not Optionable
Beta
-0.02

Key Executives

  • Mr. Rick Pauls MBA (Age 47)
    CEO, Pres & Director
  • Dr. Todd A. Verdoorn Ph.D.
    Chief Scientific Officer
  • Mr. Scott B. Kellen (Age 53)
    CFO & Company Sec.
  • Mr. Edward B. Rady (Age 69)
    Chief Commercial Advisor
  • Dr. Dennis D. Kim M.D. (Age 48)
    MBA, Consulting Chief Medical Officer













DMCAF Stock - Frequently Asked Questions

How has DiaMedica Therapeutics' stock price performed in 2022?

DiaMedica Therapeutics' stock was trading at $3.73 on January 1st, 2022. Since then, DMCAF stock has decreased by 54.7% and is now trading at $1.69.
View the best growth stocks for 2022 here
.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMCAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMCAF stock can currently be purchased for approximately $1.69.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics (OTCMKTS:DMCAF) has a market capitalization of $265.57 million.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The official website for DiaMedica Therapeutics is www.diamedica.com. The company can be reached via phone at 763-496-5454 or via email at ppapi@diamedica.com.

This page (OTCMKTS:DMCAF) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.